AI-Generated Summary

The highly anticipated EU Biotech Act, initially expected to move swiftly, has been postponed until late 2026. The European Commission has confirmed the formation of a joint task force, comprising DG SANTE and DG GROW, to draft the legislative proposal.

In a nutshell

This postponement could introduce uncertainty for biotech innovators and pharmaceutical companies operating within the EU, potentially affecting strategic planning and investment decisions awaiting a clearer regulatory framework.

Source: Euractiv